Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Seagen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SGEN's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: SGEN exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: SGEN exceeded the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Seagen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StSeagen Inc.'s (NASDAQ:SGEN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
1 month ago | Simply Wall StAre Seagen's (NASDAQ:SGEN) Statutory Earnings A Good Guide To Its Underlying Profitability?
1 month ago | Simply Wall StSeagen (NASDAQ:SGEN) Shareholders Have Enjoyed A Whopping 304% Share Price Gain
Is Seagen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SGEN ($185.75) is trading below our estimate of fair value ($341.31)
Significantly Below Fair Value: SGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SGEN is poor value based on its PE Ratio (68x) compared to the US Biotechs industry average (33.1x).
PE vs Market: SGEN is poor value based on its PE Ratio (68x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: SGEN is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: SGEN is overvalued based on its PB Ratio (14.4x) compared to the US Biotechs industry average (4.2x).
How is Seagen forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGEN's forecast earnings growth (41.6% per year) is above the savings rate (2%).
Earnings vs Market: SGEN's earnings (41.6% per year) are forecast to grow faster than the US market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SGEN's revenue (25% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: SGEN's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGEN's Return on Equity is forecast to be low in 3 years time (14.2%).
How has Seagen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SGEN has high quality earnings.
Growing Profit Margin: SGEN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SGEN has become profitable over the past 5 years, growing earnings by 3.1% per year.
Accelerating Growth: SGEN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SGEN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: SGEN's Return on Equity (20.9%) is considered high.
How is Seagen's financial position?
Financial Position Analysis
Short Term Liabilities: SGEN's short term assets ($2.2B) exceed its short term liabilities ($593.1M).
Long Term Liabilities: SGEN's short term assets ($2.2B) exceed its long term liabilities ($153.8M).
Debt to Equity History and Analysis
Debt Level: SGEN is debt free.
Reducing Debt: SGEN has not had any debt for past 5 years.
Debt Coverage: SGEN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SGEN has no debt, therefore coverage of interest payments is not a concern.
What is Seagen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Clay Siegall (59 yo)
Dr. Clay B. Siegall, Ph.D. co-founded Seagen Inc. (formerly known as Seattle Genetics, Inc.). in 1997 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Sie...
CEO Compensation Analysis
Compensation vs Market: Clay's total compensation ($USD14.52M) is above average for companies of similar size in the US market ($USD10.56M).
Compensation vs Earnings: Clay's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||15.25yrs||US$4.49m||0.046% |
|General Counsel||6.17yrs||US$3.97m||0.016% |
|Chief Medical Officer||2.67yrs||US$6.72m||0.019% |
|Chief Technical Officer||4.42yrs||US$3.95m||0.084% |
|VP of Investor Relations||no data||no data||no data|
|Executive VP of Corporate Strategy||no data||no data||no data|
|Executive Vice President of Corporate Development||9.75yrs||no data||no data|
|Vice President of Marketing||5.17yrs||no data||no data|
|Executive Vice President of Human Resources||no data||no data||no data|
|Executive Vice President of Commercial U.S.||no data||no data||0.024% |
|Senior Vice President of Translational Research||4.25yrs||no data||no data|
Experienced Management: SGEN's management team is seasoned and experienced (5.7 years average tenure).
|Independent Director||7yrs||US$442.77k||0.012% |
|Independent Director||15.83yrs||US$445.63k||0.024% |
|Independent Director||13.58yrs||US$431.04k||0.025% |
|Lead Independent Director||15.92yrs||US$482.74k||0.11% |
|Director||0.42yr||no data||0.00099% |
|Independent Director||20.58yrs||US$427.60k||0.028% |
|Independent Director||8.83yrs||US$435.63k||0.012% |
|Independent Director||2.83yrs||US$433.04k||0% |
Experienced Board: SGEN's board of directors are seasoned and experienced ( 13.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SGEN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.
Seagen Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Seagen Inc.
- Ticker: SGEN
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$33.601b
- Shares outstanding: 180.90m
- Website: https://www.seagen.com
Number of Employees
- Seagen Inc.
- Building 3
- 21717 30th Drive S.E
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SGEN||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Mar 2001|
|SGT||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2001|
|SGEN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Shares||MX||MXN||Mar 2001|
|S1GE34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 20 REPR 1 COM NPV||BR||BRL||Oct 2020|
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (A...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 23:04|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.